On the Record · Emergent BioSolutions
Emergent BioSolutions acquisitions, on the record
The businesses Emergent BioSolutions bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Bavarian Nordic (travel health business)Word for word“On May 15, 2023, pursuant to the Purchase and Sale Agreement, we completed the previously announced sale to Bavarian Nordic of our travel health business, including rights to Vaxchora ® and Vivotif ® , as well as our development-stage chikungunya vaccine candidate CHIKV VLP, our manufacturing site in Bern, Switzerland and certain of our development facilities in San Diego, California for a cash purchase price of $270.2 million, subject to certain customary adjustments.” 10-K for 2023 | divestiture | May 15, 2023 | $270.2 million |
Exclusive worldwide rights to brincidofovir from Chimerix Inc.Word for word“On September 26, 2022, we acquired exclusive worldwide rights to brincidofovir from Chimerix Inc. for the treatment of any human smallpox disease or any other disease caused by any orthopox virus.” 10-K for 2023 | acquisition | September 26, 2022 | — |
Adapt Pharma Inc.Word for word“NARCAN ® Nasal Spray, a product we obtained in connection with our acquisition of Adapt Pharma Inc. in 2018, is an intranasal formulation of naloxone approved by the FDA and Health Canada for the emergency treatment of known or suspected opioid overdose as demonstrated by respiratory and/or central nervous system depression.” 10-K for 2023 | acquisition | 2018 | — |
Bora Pharmaceuticals Injectables Inc. (Drug Product facility in Baltimore-Camden)Word for word“At closing, Bora paid a cash purchase price of approximately $35.0 million, which included customary closing adjustments for working capital and transaction expenses of the business.” 10-K for 2024 | divestiture | — | approximately $35.0 million |
SERB (RSDL Reactive Skin Decontamination Lotion)Word for word“including RSDL ® (Reactive Skin Decontamination Lotion), which was acquired by SERB on July 31, 2024.” 10-K for 2024 | divestiture | acquired by SERB on July 31, 2024 | — |
travel health businessWord for word“In 2023, we completed the sale of our Commercial Products Segment's travel health business, including rights to Vivotif ® , the licensed typhoid vaccine; Vaxchora ® , the licensed cholera vaccine; the development-stage chikungunya vaccine candidate CHIKV VLP; the Company’s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California to Bavarian Nordic.” 10-K for 2025 | divestiture | 2023 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2016-12-31 | $0 | — | $0 |
| 2017-12-31 | $117.5 million | — | $8,100 |
| 2018-12-31 | $827.7 million | — | $210.6 million |
| 2019-12-31 | $0 | — | $0 |
| 2020-12-31 | $0 | — | $100,000 |
| 2022-12-31 | — | $0 | — |
| 2023-12-31 | — | $270.2 million | — |
| 2024-12-31 | — | $110.2 million | — |
| 2025-12-31 | — | $0 | — |
Deal filings since 2016
- 2026-06-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-04-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-09-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-10-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-09-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-07-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-07-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-05-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-04-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-03-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-05-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-05-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-05-15 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2023-04-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-02-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-09-26 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2022-05-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-10-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-07-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-08-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-07-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-07-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-06-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-09-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-10-15 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2018-10-05 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2018-08-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-08-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-10-06 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-10-03 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-10-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-07-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-07-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-03-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-12-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-09-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-08-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-08-04 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
Read from Emergent BioSolutions’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-27. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.